Introducing the Anti-Mouse CD96 In Vivo Antibody - Low Endotoxin from Assay Genie, a highly specific monoclonal antibody designed for in vivo applications. This antibody targets the CD96 protein, essential in immune cell interaction, making it ideal for research in immunotherapy, oncology, and hematologic studies. With a rat IgG2a isotype, it ensures high purity and low endotoxin levels (<1.0 EU/mg), perfect for ELISA, flow cytometry, functional assays, and other experimental applications. Available in various sizes, it is formulated in phosphate-buffered saline for stability and efficacy.
Enhance your research with this reliable and versatile antibody. CD96, also known as Tactile, is a member of the immunoglobulin superfamily expressed primarily on the surface of natural killer cells and T-cells. It plays a significant role in the adhesion to target cells and the modulation of immune responses, providing a valuable target for therapeutic research in cancer and immune-related disorders.
Product Name:
Anti-Mouse CD96 In Vivo Antibody - Low Endotoxin
Product Code:
IVMB0294
Size:
1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:
3.3
Protein:
CD96
Product Type:
Monoclonal Antibody
Synonyms:
Tactile (T cell-activated increased late expression)
Isotype:
IgG1 k
Reactivity:
Mouse
Applications:
B, FC, In Vivo
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:
B, FC, In Vivo
Reactivity:
Mouse
Host Species:
Rat
Specificity:
Clone 3.3 recognizes an epitope on mouse CD96.
Antigen Distribution:
Mouse CD96 is mainly expressed by cells of hematopoietic origin, particularly T cells and NK cells.
Immunogen:
Not available or unknown
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
CD96 is a single pass type I transmembrane glycoprotein in the immunoglobulin superfamily that is heavily N-glycosylated1. Murine (m) CD96 is present at the surface of most lymphocytes, including NK, CD4+ T, CD8+ T, NKT, and gammaδ T cells, but not B lymphocytes, neutrophils, macrophages, or dendritic cells2. mCD96 interacts with mCD155 and nectin-1 (CD111)1. A V-like domain mediates binding of mCD96 to mCD155 via interaction between amino acids of the FG loop of one binding partner with residues in the C’C’’-loop of the other. CD96 is a member of an interaction network that includes adhesion, activation, and inhibition activities.
CD96 contains three Ig-like domains that are separated from the transmembrane domain by a long proline, serine, and threonine rich stalk that undergoes extensive O-linked glycomodification1. The stalk may play a role in orientation or presentation of the Ig-like domains. mAb 3.3 binds to the first Ig domain and competes with CD155 for binding3.
Human CD96 has a mild boosting effect on 2B4- and NKp30-mediated killing, but a direct role in the activation of NK cell-mediated cytotoxicity in vitro has not been observed 1. In contrast, mCD96 suppresses NK cells in vivo2. Blocking studies show that mCD96 competes with CD226 for CD155 binding and limits NK cell function by direct inhibition2. Additionally, blocking mCD96 in vivo with mAb 3.3 protects against metastasis in three different tumor models. The antimetastatic effect of mAb 3.3 is independent of antibody-dependent cell-mediated cytotoxicity and activating Fc receptors3,4 and is enhanced by anti-PD-1 and anti-CTLA-4 mAbs4. Suppression of metastasis by mAb 3.3 is dependent on NK cells, CD226 (DNAM-1), and IFN-gamma4. Additionally, mAb 3.3 loses its antimetastatic function in CD155- and IL-12p35-deficient mice3.
